About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
Financial | Nanobiotix 2018 Annual Results
15 March 2019
Scientific Clinical | Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
2 April 2019
Scientific Clinical | Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
Published by
Candice Teo
on
26 March 2019
No translations available for this page
